G&E Herbal Biotechnology Co., Ltd.
G&E Herbal Biotechnology Co., Ltd. engages in development and commercialization of novel botanical extraction technology and products in Taiwan. It offers Hepanamin capsules; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as adult products, in… Read more
G&E Herbal Biotechnology Co., Ltd. (4911) - Total Liabilities
Latest total liabilities as of September 2025: NT$66.45 Million TWD
Based on the latest financial reports, G&E Herbal Biotechnology Co., Ltd. (4911) has total liabilities worth NT$66.45 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
G&E Herbal Biotechnology Co., Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how G&E Herbal Biotechnology Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
G&E Herbal Biotechnology Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of G&E Herbal Biotechnology Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clarke Inc
PINK:CLKFF
|
USA | $331.58 Million |
|
PCC Rokita SA
WAR:PCR
|
Poland | zł963.17 Million |
|
Helios Fairfax Partners Corporation
PINK:FFXXF
|
USA | $22.53 Million |
|
QUALITAS SEMICONDUCTOR CO. LTD.
KQ:432720
|
Korea | ₩39.71 Billion |
|
Mobiletron Electronics Co Ltd
TW:1533
|
Taiwan | NT$5.87 Billion |
|
Daaz Bara Lestari Tbk
JK:DAAZ
|
Indonesia | Rp4.28 Trillion |
|
Nitratos de Chile SA
SN:NITRATOS
|
Chile | CL$355.37 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down G&E Herbal Biotechnology Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how G&E Herbal Biotechnology Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for G&E Herbal Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual total liabilities of G&E Herbal Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$125.64 Million | +4.82% |
| 2023-12-31 | NT$119.86 Million | +30.37% |
| 2022-12-31 | NT$91.94 Million | +959.34% |
| 2021-12-31 | NT$8.68 Million | -- |